EPOMI Study: ErythroPOietin in Myocardial Infarction (EPOMI)
ErythroPOietin in Myocardial Infarction
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Angers, France, 49933
- CHU Angers
-
Angers, France, 49933
- Fabrice PRUNIER, MD, PhD,
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- ST-Segment elevation myocardial infarction <6h
- Infarct related artery : proximal circumflex artery , proximal and mid left anterior descending artery, 1st segment of the right coronary artery
- TIMI 0 or 1 before angioplasty
- Successful PCI defined by residual stenosis < 50% and TIMI 2 or 3 flow grade
- Body weight : [50-110] kg
- Informed, written consent
Exclusion Criteria:
- Age < 18
- Pregnant, or parturient or breast-feeding women;
- Sexually active women without efficient contraception;
- Inability to fully cooperate with the study protocol
- Pre-treatment with fibrinolysis ;
- Previous Q-wave myocardial infarction or previous aorto-coronary bypass;
- History of deep vein thrombosis or pulmonary embolism;
- Contraindication to aspirin or clopidogrel ;
- Cardiogenic shock ;
- Cardiac resuscitated before angioplasty ;
- Past or active erythropoietin therapy;
- Contraindications to erythropoietin therapy: uncontrolled hypertension, known hypersensitivity to benzoic acid, chronic liver insufficiency, hemoglobin> 16g / l, thrombocytosis, refractory anemia with excess of blasts;
- Renal insufficiency (creatinine clearance <30ml/mn.);
- Active Malignancies
- Any contraindications to magnetic resonance imaging: pacemaker and automatic cardiac defibrillator, hearing aid, neurostimulator, infusion pump etc metallic splinters in the eye, ferromagnetic haemostatic clips in the central nervous system cochlear implants, claustrophobia;
- Allergy to gadolinium ;
- Patient refusal / patient not having provided written informed consent.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: 1
|
Single Injection of 1000 U/kg Erythropoietin beta IV immediately after primary PCI
|
|
No Intervention: 2
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Changes in infarct size as assessed by magnetic resonance imaging 3 months after administration of study medication
Time Frame: within 3-7 days of administration of study medication
|
within 3-7 days of administration of study medication
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
End-systolic volume, end-diastolic volume, ejection fraction
Time Frame: within 3-7 days of administration of study medication, and 3 months later
|
within 3-7 days of administration of study medication, and 3 months later
|
|
Changes in hemoglobin, platelets, reticulocytes blood count
Time Frame: during the first 10 days following study medication administration
|
during the first 10 days following study medication administration
|
|
Occurrence of major cardiac event or venous thrombotic events
Time Frame: within 12 months following administration of study medication
|
within 12 months following administration of study medication
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Fabrice Prunier, MD, PhD, University Hospital, Angers
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- PHRC 2007-03
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.